• Biodesix: 216 of the Inc500 for 2015

    September 4, 2015 “Biodesix discovers and commercializes cancer tests that help patients and their doctors make more informed decisions about treatment based on a patient’s unique molecular profile….” Read more at inc.com HOME CONTACT PRIVACY TERMS and CONDITIONS CAREERS FAQ SITE MAP NEWS GRANTS TERMS OF USE This site is for informational purposes only and is not intended to be a substitute for medical advice from a physician. Please check with ... Read more
  • Study: better NSCLC outcomes with proteomic test

    April 9, 2015 The VeriStrat proteomic test, when used to help guide treatment of patients with advanced non-small cell lung cancer, improves overall survival and decreases medical costs in the U.S. payer system, said a study published recently in the journal Lung Cancer. “Systems of care ... Read more
  • Biodesix Launches GeneStrat Targeted Liquid Biopsy Mutation Test For Patients With Advanced Lung Cancer

    May 21, 2015 Diagnostic Test Reveals Actionable Mutations; Results Returned Within 72 Hours Biodesix, Inc. today announced the launch of GeneStrat™, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC).  The blood test results are ... Read more
  • United Healthcare Approves Coverage for Biodesix’ VeriStrat Test

    May 12, 2015 Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from United Healthcare (NYSE: UNH), one of the largest commercial insurance company in the US, with a published 44.7 million covered lives. In its Medical Policy (#2015T0535EE), United Healthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung ... Read more
  • AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress

    September 24, 2014 VeriStrat “Poor” Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify ... Read more
  • New technology for the proteomic age (Nature publication)

    September 12, 2013 A leader in protein-based diagnostic tests, Biodesix is improving the precision of applying personalized medicine by advancing beyond the exploration of genes To the researchers at Biodesix, the genomic age is a rest stop along the road to even more precisely targeted therapies and applications. They are ... Read more
  • Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

    June 3, 2013 Biodesix, a Boulder, CO-based company that develops molecular diagnostic tests, said today that it has passed a key clinical trial that shows its VeriStrat test can give physicians a better idea of what to do next after the first round of treatment for non-small cell lung cancer has ... Read more
  • Putting Lung Cancer in the Bullseye (Breakthroughs)

    September 25, 2012 Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. She’s deep into researching targeted therapies for lung cancer so she can offer up better treatment options. The disease has been the leading cause of cancer deaths for a long time, but researchers like her ... Read more
  • Biodesix Feels the Buzz at BIO2012 (FierceBiomarkers)

    July 26, 2012 Paul Beresford, vice president of business development and strategic marketing at Biodesix, spoke to FierceBiomarkers ahead of his appearance on the BIO2012 panel “Commercialization of Personalized Medicine: Stakeholders’ Recipe For Success.” So what is Biodesix’s own recipe for success? Keeping it collaborative and ... Read more
  • A Test to Go With It (GenomeWeb)

    July 10, 2012 Personalized medicine promises to tailor treatments to patients’ diseases, so to determine whether a drug is suitable for a given patient, pharmaceutical companies are increasingly turning to companion diagnostic tests — tests that, by definition, are necessary to decide if a course of treatment is right for a particular patient. Many ... Read more